Sarepta Therapeutics (SRPT) PT Lowered to $35 at Oppenheimer

August 6, 2026 8:37 AM

Oppenheimer analyst Andreas Argyrides lowered the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $35.00 (from $37.00) while maintaining a Outperform rating.

No results found